Format

Send to

Choose Destination
See comment in PubMed Commons below
Anticancer Res. 2006 Nov-Dec;26(6C):4705-11.

Positron emission tomography with F-18 fluorodeoxyglucose in evaluating colorectal hepatic metastasis down-staged by chemotherapy.

Author information

1
Department of Hepato-biliary Pancreatic Surgery, National Cancer Center Hospital East, Chiba, Japan. shtakaha@east.ncc.go.jp

Abstract

BACKGROUND:

The efficacy of positron emission tomography with 18F fluoro-2-deoxy-D-glucose (FDG-PET) is obscure in evaluating viability or the extent of colorectal hepatic metastasis (CHM), down-staged by chemotherapy.

PATIENTS AND METHODS:

A retrospective lesion-by-lesion analysis was performed for seven consecutive patients, who had received rescue hepatectomy for initially unresectable CHM, in order to evaluate the correlation between results of imaging modalities and the corresponding pathology.

RESULTS:

The sensitivity and positive predictive value of the conventional modalities (CT and MRI) were 92% and 42%, respectively, while the sensitivity, specificity, positive predictive value and negative predictive value of FDG-PET were 58%, 100%, 100% and 75% respectively. The sensitivity of FDG-PET was 100% in evaluating the viability of tumors >2 cm, however, this fell to 17% in tumors <2 cm.

CONCLUSION:

FDG-PET is effective in assessing the viability of tumors >2 cm, but not those <2 cm, in patients with CHM down-staged by chemotherapy.

PMID:
17214330
[Indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Support Center